Immunitas Therapeutics, a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/immunitas-therapeutics-launches-with-39-million-series-a-to-advance-lead-programs-to-human-efficacy-studies-based-on-a-unique-human-immunology-focused-drug-development-platform-5872